Obesity-related comorbidities common in overweight patients with IBD

December 27, 2021

1 min read


Rosenblum M, et al. Poster 131. Presented at: North American Society for Pediatric Gastroenterology, Hepatology & Nutrition Annual Meeting; Dec. 12-18, 2021 (virtual meeting).

Healio was unable to confirm relevant financial disclosures at the time of publication.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Pediatric patients with inflammatory bowel disease who were overweight and underwent screening were found to often have obesity related comorbidities, suggesting screening should be routine for this population, according to a poster.

“The prevalence of obesity-related comorbidities in the adult IBD population is well characterized in the literature, however there is limited research on this topic in the pediatric IBD population at this time,” Matthew Rosenblum, MD, of the University of California, San Francisco Benioff Children’s Hospital in Oakland, California, and colleagues wrote in the poster presented at the North American Society for Pediatric Gastroenterology, Hepatology & Nutrition Annual Meeting.

The researchers enrolled 137 pediatric patients (median age, 18 years; 53% male; 40% white; private insurance, 56%) diagnosed with ulcerative colitis (37.2%), Crohn’s disease (49.6%) or unclassified IBD (13.1%) who attended the UCSF Benioff Children’s Hospitals in San Francisco or Oakland between November 2019 and April 2021. Patients were included if they met the CDC criteria for overweight and obesity.

Previous severe disease was reported in 39% of patients with UC while 12.9% of patients with CD had stricturing or penetrating disease and 4% underwent surgery.

Monoclonal antibodies were actively used in 70.8% of patients with 55.7% using infliximab; only 1.5% of patients were on systemic steroids. Previous infliximab use was reported in 13.1% of patients and previous systemic steroid use was reported in 19.7%. There were at least three medication changes among 40% of patients, two changes among 21% of patients, one change among 11% of patients and no changes among 28% of patients.

“This study population appeared to have difficulty achieving long-term remission as evidenced by requiring multiple medication changes since diagnosis,” Rosenblum and colleagues reported.

Researchers further performed lipid panel screening in 61 patients (44.5%), 32 of whom had dyslipidemia. MRI results were available for 119 patients (87%) and 19 of those had hepatic steatosis.

Among 64 patients (47%) with HbA1c results, 10 patients had prediabetes and 2 patients had type 2 diabetes. Four out of 63 patients who identified as female were diagnosed by an endocrinologist with polycystic ovary syndrome.

“Our study suggests that routine screening for obesity-related comorbidities is an important factor in providing comprehensive care to overweight and obese patients with IBD,” according to the poster.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.